After 2 months of monitoring for symptoms of cutaneous reactions, a mild, transient rash was found to develop in 4.3% of the subjects, but SJS/TEN did not develop in any of the HLA-B*15:02-negative subjects receiving the same drug. The gene discussed is HLA-B; the disease is toxic epidermal necrolysis.